Tom

About Tom Rauscher

This author has not yet filled in any details.
So far Tom Rauscher has created 10 blog entries.

New White Paper: Pathways of Care, Shifting Financial Risk and Value Frameworks – Where is the Oncology Market Heading?

2020-07-19T18:50:37+00:00July 19th, 2020|Categories: Blog|

Historically, the management of oncology drugs in the U.S. has remained relatively hands-off, despite high budget impact. However, the situation may be changing. Recently, there has been discussion around new management tools, shifting of financial risk, and the influence of value frameworks. In June 2020, Two Labs conducted a panel with payers, hematology and oncology providers, and representatives from several big pharma and small biotech companies with oncology [...]

Why Manufacturers Launching Specialty Drugs Need Trade Management

2020-06-22T17:27:24+00:00June 19th, 2020|Categories: Blog|

Launching a drug isn’t easy. All manufacturers, no matter the classification of product they create, face challenges on the journey to bring their drug to market. However, due to the nature of their dose form, complex storage needs, stability requirements, and costs, manufacturers launching specialty drugs must often navigate more hurdles than those dealing with a traditional retail product. Not appropriately planning for or inaccurately handling these hurdles [...]

COVID-19 Q&A: How will the outbreak impact DSCSA

2020-06-03T14:26:01+00:00June 3rd, 2020|Categories: COVID-19|Tags: |

COVID-19 is impacting the healthcare system in a way we’ve never seen before, and pharmaceutical manufacturers are facing new challenges at rapid speeds. To help keep you informed, we’re releasing a special Q&A series with our experts to discuss the virus’s impact on each stage of the launch journey. Today, we spoke with DSCSA and Serialization Services Manager Michael Rowe about the effect of COVID-19 [...]

COVID-19 Q&A: How will the outbreak impact U.S. pharmaceutical marketing and promotions

2020-05-19T15:03:20+00:00May 19th, 2020|Categories: COVID-19|Tags: |

COVID-19 is impacting the healthcare system in a way we’ve never seen before, and pharmaceutical manufacturers are facing new challenges at rapid speeds. To help keep you informed, we’re releasing a special Q&A series with our experts to discuss the virus’s impact on each stage of the development journey. Today, we spoke with David Ward, Vice President for EHRx Solutions, Sara Stricker, Manager at CEEK [...]

COVID-19 Q&A: How will the outbreak impact small companies

2020-05-18T14:14:46+00:00May 15th, 2020|Categories: COVID-19|Tags: |

Timing Funding PUBLIC FUNDING If a manufacturer has received public funding, they are feeling the effects of the stock market downturn and may need to find ways to decrease budget and/or bring about additional funding sources. PRIVATELY FUNDED If a manufacturer has received funding from private investors, there may be more inherent cash security, but they must [...]

Jack Ericsson Joins Two Labs as Business Development Director

2020-05-04T14:11:52+00:00May 2nd, 2020|Categories: Blog|

At Two Labs, we know that our clients are looking for solutions. Every service we offer is about paving the way for our clients to launch their products to the market and into the hands of patients who need them. As we continue to grow, and especially as we evaluate our new reality during and after the COVID-19 pandemic, our focus is on connecting the dots to help [...]

Two Labs Joins GS1 Healthcare US Initiative

2020-03-13T12:36:34+00:00March 13th, 2020|Categories: Blog|

Two Labs Joins GS1 Healthcare US Initiative Two Labs is a new member of the GS1 Healthcare US Initiative and will be joining the Rx Supply Chain Security Workgroup (RxSSC) in 2020.The GS1 Healthcare US Initiative includes over 140 healthcare manufacturers, distributors, providers, dispenser pharmacies, group purchasing organizations, government agencies and industry associations who are working together to help address challenges where GS1 Standards can have an impact. [...]

Pricing and Market Access Considerations for Cell and Gene

2020-03-04T22:43:35+00:00February 27th, 2020|Categories: Blog|Tags: , , , |

Pricing and Market Access Considerations for Cell and Gene In the past two years, four cell and gene therapies have entered the U.S. market at unprecedented prices. Most recently, Zolgensma launched at a price of $2.1 million for a one-time treatment. Payers view these new therapies as having moderate to high clinical value but have significant concerns around long term durability of effect. For example, will [...]

What is Compendia’s Impact on Product Decision Making?

2020-03-04T13:52:02+00:00February 26th, 2020|Categories: Blog|Tags: , , |

What is Compendia’s Impact on Product Decision Making? What is “The Compendia”? Most often, people describe the organizations that make up the Compendia as price books – and that’s understandable. After all, most of the submissions a manufacturer makes to Compendia involves price increases throughout the product launch year until they maintain price on a regular basis. And yes, pricing is absolutely a key part of what they do, however, [...]

An Overview of Cell and Gene Therapies

2020-03-04T13:53:10+00:00February 24th, 2020|Categories: Blog|Tags: , , , |

An Overview of Cell and Gene Therapies Since 2017, four new cell and gene therapies have become available in the U.S. with prices ranging from $373,000 to $2.1 million for a one-time administration. Gene Therapy Launch Timeline Gene Therapy Product Overview Product Indication Therapy Type Price Kymriah Childhood B-cell acute lymphoblastic leukemia (ALL) Diffuse large B-cell lymphoma (DLBCL) CAR-T [...]

Go to Top